

10th February, 2022

CIN: L55101TG1973PLC040558

<p>The General Manager, Department of Corporate services Bombay Stock Exchange Ltd (BSE) Phiroze Jheejheebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip Code - 543308 ISIN: INE967H01017</p>	<p>The Manager, Listing Department National Stock Exchange of India Limited, Exchange Plaza, 5th Floor, Plot No.C/1, 'G' Block Bandra - Kurla Complex Mumbai - 400 051. Symbol - KIMS ISIN: INE967H01017</p>
---	---

Dear Sir,

Sub: Investor presentation

Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed herewith the Investor Presentation.


The said presentation is being uploaded on the website of the Company i.e., www.kimshospitals.com.

We request you to take this on record.


Thanking you,

Yours truly

For Krishna Institute of Medical Sciences Limited



Umashankar Mantha
Company Secretary & Compliance Officer



Krishna Institute of Medical Sciences Limited





Minister Road, Secunderabad - 500 003, Telangana, India

Phone: +91 40 4488 5000/4488 5184 | Fax: +91-40-27840980 | kimshospitals.com

CIN: L55101TG1973PLC040558



KIMS HOSPITALS™



Q3 FY'22

THE LARGEST CORPORATE
HEALTHCARE GROUP IN
ANDHRA PRADESH AND
TELANGANA



DISCLAIMER

This presentation has been prepared by Krishna Institute of Medical Sciences Limited (“KIMS” or the “Company”) solely for your information and for your use and may not be taken away, distributed, reproduced, or redistributed or passed on, directly or indirectly, to any other person (whether within or outside your organization or firm) or published in whole or in part, for any purpose by recipients directly or indirectly to any other person. By accessing this presentation, you are agreeing to be bound by the trailing restrictions and to maintain absolute confidentiality regarding the information disclosed in these materials.

This presentation does not constitute an offer or invitation to purchase or subscribe for any securities of the Company by any person in any jurisdiction, including India and the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. Securities may not be offered or sold in the United States absent registration or an exemption from registration. This presentation is not intended to be a prospectus (as defined under the Companies Act, 1956) or offer document under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 as amended.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be “forward looking statements” based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and in their opinion reasonable, including those relating to the Company’s general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

This presentation may contain statements that constitute forward-looking statements. Forward looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company’s business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such change or changes. This presentation may not be copied or disseminated in any manner.

1) Introduction to
KIMS Hospitals




2) Financial &
Operational
Updates

3) Update on
Sunshine Hospital

4) Update on
Expansion Plans



Introduction to KIMS Hospitals



1 & 2) Related to Sunshine Hospital

• DOCTORS* (1,140) • NURSES* (2,984) • PARAMEDICS* (1,651) • ADMIN* (4,651) - TOTAL: 10,426


*Excludes Sunshine Hospitals

DRIVEN BY A VISION

VISION:

To be the most preferred healthcare services brand by providing affordable care and best clinical outcomes to patients.

And to be the best place to work for doctors and employees.



- Affordable Quality Care
- Best-in-Class Facilities
- Patient Centric Systems & Processes

- Clinical Outcome Driven Excellence
- Latest Medical Technology
- Strong Academics & Research Oriented

- Enriching Atmosphere
- Collaborative Culture
- Growth Driven Career Approach

- Transparent Governance
- Strong Operational Performance
- Consistent Growth

Procedure	Dept. Volume	Technology	Achievements
Cardiac Sciences Angioplasty, Bypass Surgery, Bentall Procedure, TAVI, EP Studies & Device Closure	> 2196/month	Cathlab Impella Device Heart Lung Machine	<ul style="list-style-type: none"> • One of the largest and most experienced cardiac sciences team in South India • Maximum number of Bentall procedure and midtrial valvule repairs done in AP & Telangana • First centre in India to perform Arch repair in Neonates and infants without TCA
Oncological Sciences IORT, IGRT, IMRT, Robotic cancer surgeries	> 727/month	Robotics Novalix TX PET, Gamma Camera	<ul style="list-style-type: none"> • Over 700+ Robotic Cancer Surgeries done • First hospital in South India to perform Total Skin Electron Beam Therapy
Neuro Sciences Craniotomy Brain Tumour Stroke, Epilepsy Surgeries	> 953/month	O-Arm Robotics Stealth Station S8	<ul style="list-style-type: none"> • Over 1000 Epilepsy surgies done • Largest Neuro Program in South India • 3rd Best Hospital for Epilepsy in India • Diamond Award for Stroke Program
Gastro Sciences Bariartic Surgery Minimally Invasive GI surgeries	> 624/month	Fibroscan Enteroscan 190 Series Endoscope	<ul style="list-style-type: none"> • One fo the few centres in South India to do advanced third space endoscopic procedures • 2nd hospital in South India to do GERDX procedure • One of the few centres in India to perform Endoscopic Suturing procedures for complex cases
Ortho Sciences Knee / Hip Replacement, Sport Injuries, Trauma	> 562/month	Navigation System	<ul style="list-style-type: none"> • Expertise in complex trauma and complex revision & replacement surgeries • Over 5000 replacement surgeries done
Renal Sciences Prostate, Nephretomy, Laser Kidney Stones	> 1725/month	CRRT Dialysis Machines Robotics	<ul style="list-style-type: none"> • Largest Renal Transplant Program in India • Highest number of Dialysis Machines in Hyderabad in a single unit
Transplantation Heart, Lung, Kidney, Liver, Pancreas & Bone Marrow	Heart & Lung > 8/month Liver > 8/month Kidney > 14/month	ECMO Heart Lung Machines X-Vivo	<ul style="list-style-type: none"> • Highest Covid Double Lung Transplants outside of USA • India's first breathing Lung Transplant done • Pioneers in Kindney Transplant in India • Liver Transplant program is among Top 3 in AP & Telangana • Bone Marrow Transplant program is among Top 2 in AP & Telangana

MULTI SPECIALTY CARE

Brain

- Neurology
- Neurosurgery
- Psychiatry
- Neuro Rehabilitation

Heart

- Cardiology
- Cardiac Surgery
- Vascular Surgery
- Heart Transplant
- Cardio Rehabilitation

Lung

- Pulmonology
- Interventional Pulmonology
- Thoracic surgery
- Lung Transplant

ENT

- Ear
- Nose
- Throat
- Head and Neck Surgery

Eyes

- Ophthalmology

Gastro Intestinal Tract

- Medical Gastroenterology
- Surgical Gastroenterology
- Hepatobiliary Pancreatic Surgery

- Liver Transplant

- Bariatric Surgery

Genito Urinary Tract

- Nephrology

- Urology

- Andrology

- Renal Transplant

- Gynecology

- Urogynecology

- IVF and ART

- Fetal Medicine

- Obstetrics

Oncology

- Medical Surgical and Radiation

- BMT and Hematology

Bones and Spine

- Orthopedics
- Arthroscopic Surgery
- Spine Surgery
- Ortho Rehabilitation

Skin

- Dermatology
- Cosmetology
- Plastic and Reconstructive Surgery

Orthodontics

- Maxillo Facial Surgery

Anaesthesia

- OT Anaesthesia
- Day care Anaesthesia
- Pain Medicine

General Specialities

- Internal Medicine
- General Surgery
- Diabetology & Endocrinology

Pediatrics

- Pediatrics & Pediatric Sub Specialities
- Neonatology

Radiology

- Imaging
- Interventional Radiology

Lab Services

- Pathology
- Microbiology
- Biochemistry
- Molecular Biology
- Clinical Hematology

Critical Care Services

- ICU
- CTICU
- SICU
- NICU
- PICU
- Neuro ICU
- ECMO ICU
- Post Transplant ICU

Hospital Infection Control

- Clinical Infectious Diseases



4-Arm HD da Vinci Robotic Surgical System

Facilitates complex surgeries that are virtually scar less



O-Arm Scanner

Multi-dimensional surgical imaging platform optimized for use in spine, orthopaedic, and trauma-related surgeries



Spy Glass

State of the art add on to ERCP that allows doctors to observe patients' biliary duct system and other tiny ducts in the pancreas



Novalis Tx Linear Accelerator

Machine used in radiosurgery and radiotherapy for treating cancer patients



3 Tesla MRI

Non-invasive diagnostic imaging technique performing faster scans and gives improved diagnostic sensitivity and specificity



Fibroscan

Specialized non-invasive diagnostic ultrasound-based device that measures fibrosis and steatosis caused by different liver diseases



EBUS

Used to diagnose lung cancer, infections, and other diseases causing enlarged lymph nodes in the chest




STEALTH STATION S8

Provides the Neuro surgeon to use data intraoperatively for advanced visualization.




IMPELLA

Impella, the world's smallest heart pump, is a percutaneous catheter-based technology that provides hemodynamic support to the heart



SHAREHOLDING PATTERN - 31ST DECEMBER, 2021



As on 31st Dec 2021

Top Shareholders - DII / FII

Share Holder	Share Holding %	Category
ICICI Ventures	2.4%	DII
Mirae Asset MF	7.5%	DII
Axis MF	3.8%	DII
Nomura	2.2%	FII
Polar Capital Fund	1.9%	FII
Invesco MF	1.9%	DII
Government Pension Fund Global	1.6%	FII
TATA AIA Life Insurance	1.3%	DII
HDFC Life Insurance	1.3%	DII
PGIM MF	1.2%	DII
IIFL Asset Management	0.7%	FII

Financial and Operational Updates

FINANCIAL HIGHLIGHTS*

Q3 FY 21-22

- Consolidated operating revenue saw an increase of 10% against Q3 of FY 21, standing at Rs. 3,960 million.
- Consolidated EBITDA for Q3 FY 22 stood at Rs. 1,322 million, a growth of 42% against Q3 FY 21. EBITDA margins expansion was driven by speciality mix change over FY 21 last year and operation leverage
- Consolidated PAT of Rs. 842 million in Q3 FY22 at 21% compared to Q3 of FY 21 was 13%
- EPS on diluted basis has increased to Rs.10.1 in Q3 FY 22 from Rs. 6.5 in Q3 FY 21

9M FY 21-22

- Consolidated Total Income saw an increase of 32% to Rs 12,906 million against 9M FY20-21 standing at Rs 9,774 million
- Consolidated EBITDA grew by 50% Rs. 4,143 million, mainly due to case mix, payer mix and cost optimisation
- EBIDTA Margin grew to 32% in 9M FY22 from 28% in 9M FY 21 primarily led by tighter cost control on operating expenses and operating leverage.
- Consolidated PAT saw an increase of 77% to Rs. 2605 million against 9M FY20-21 standing at Rs 1,469 million
- EPS on diluted basis has increased to Rs. 33.3 in 9M FY 22 against 9M FY 21 of Rs. 19.0

OPERATIONAL HIGHLIGHTS

- 9M FY 22 occupancy stood at 63% against 53% in 9M FY 21
- IP volume grew by 24% & OP Volume grew by 31% during 9M FY 21-22 vs 9M FY 20-21 driven by near normalization in major specialities.
- ARPOB improved to Rs. 24,186 during 9M FY 21-22 vs Rs. 21,813 during 9M FY 20-21. This was mainly driven by better payor mix and increase in complex surgeries and procedures.
- ALOS has improved to 5.1 days from 5.3 days during 9M FY 21-22 vs 9M FY 20-21
- ARPP has increased from Rs. 1.15 Lakhs in 9M FY 21 to Rs. 1.23 Lakhs in 9M FY 22, which is a growth of 7%.

DIGITAL INITIATIVES

During the quarter, steady progress was made on digital transformation with notable initiatives as below:

- KIMS Hospitals sponsored the 'FHIR Connectathon' and a team of 16 members participated to build capability and show commitment to interoperability in healthcare.
- Remote patient monitoring technology was deployed in the wards, integrated with a digital nursing application.
- Digital applications were flexible to meet the needs of bed management and telemedicine consultation of Omicron Covid cases resulting in a safer and convenient patient experience during challenging times.

KIMS Hospitals is well on the way to take the next steps in doctors ordering tests on a mobile app, completely digital patient experience and resource optimization. Several initiatives are planned in the JFM quarter that will take digital to the next level at all units of the group.

ESG INITIATIVES


KIMS, Secunderabad has partnered up with Smart Joules Pvt Ltd (SJPL) a prominent Energy Services Company (ESCO) in 2018. A new and innovative model known as JoulePAYS was executed wherein, KIMS makes Zero Capital investment to implement various Energy Conservation Measures (ECMs) across the hospital and gets a guaranteed energy savings of minimum 10% annually over the baseline energy consumption.

- 22.3% of total energy consumption saved
- INR 66.5 lakhs of energy cost saving achieved
- 537 tonnes of CO₂ saved


In real life translation, the above translates to approximately the following:

- 8,841 households getting electricity
- 22 Lakhs KMs less driven
- 22,000 trees planted


SPECIALITY MIX




PAYOR MIX



CLUSTER REVENUE*




CLUSTER EBIDTA*




1) AP Matured: Nellore, Rajahmundry and Srikakulam
 2) AP Non-Mature: Ongole, Vizag, Ananthpur and Kurnool
 3) Telangana: Secunderabad & Kondapur


IP VOLUME




OP VOLUME



OCCUPANCY*




ARPOB




*Occupancy %: Based on Beds Capacity


REVENUE




EBITDA



PBT



PAT



*Including share profit of Joint Venture (Sunshine)

GROUP OPERATING PERFORMANCE 3/3

Particulars	FY19	FY20	FY21	FY22 9M
Bed Capacity	2,804	3,004	3,064	3,064
Occupancy	49%	56%	58%	63%
IP volume	111,382	140,676	116,592	104,143
OP volume	900,043	1,137,560	830,211	742,862
ARPOB	18,334	18,307	20,609	24,186
ARPP	81,995	79,526	113,904	123,089
ALOS	4.47	4.34	5.53	5.09
Revenue	9,239	11287	13401	12906
EBITDA	1,740	2,511	3,810	4,143
EBITDA %	19%	22%	28%	32%

1) Occupancy %: Based on Beds Capacity

2) FY19 EBITDA is adjusted towards the loss on FV changes in Financial Instruments

COMPARISON OF ANDHRA PRADESH MATURE HOSPITALS & ANDHRA PRADESH ACQUIRED HOSPITALS

Particulars	Matured Assets				Acquired Assets			
	FY19	FY20	FY21	9M FY22	FY19	FY20	FY21	9M FY22
Bed Capacity	570	570	630	630	1034	1234	1234	1234
Occupancy	67%	66%	66%	71%	32%	48%	62%	65%
IP volume	33,861	36,972	30,503	23,710	24,221	46,393	41,002	40,075
OP volume	221,322	248,774	209,178	144,924	225,375	389,995	289,324	279,117
ARPOB	13,558	14,961	13,608	13,978	8,705	9,727	9,881	11,911
ARPP	55,492	55,810	67,303	72,225	44,050	45,604	67,381	65,034
ALOS	4.09	3.73	4.95	5.17	5.06	4.69	6.82	5.46
Revenue	1,890	2,072	2,060	1,716	1,073	2,127	2,781	2,622
EBITDA	427	478	526	422	-31	116	468	569
EBITDA %	23%	23%	26%	25%	-3%	5%	17%	22%

Bed Capacity:

New Clinical specialities of Oncology, Vascular Surgeries and Mother & Child are planned in Ongole, Vizag and Anantapur. This will see addition of Bed and better occupancy in these units.

ARPOB and ARPP:

ARPOB and ARPP of Acquired assets have enough headroom to grow to the same levels of Mature Assets.

ALOS:

Further reduction of ALOS in Acquired assets is possible as we continue to optimise costs in these units.

EBIDTA:

EBIDTA Margin of Acquired assets has potential to reach the same levels of Mature assets basis our learnings from the same.

1) Matured assets: Nellore, Rajahmundry and Srikakulam 2) Acquired assets: Ongole, Vizag, Ananthpur and Kurnool
 3) Occupancy %: Based on Beds Capacity 4) Revenue & EBITDA: Before inter company eliminations

PROFIT AND LOSS STATEMENT

(RS. MILLIONS)

Particulars	9M FY 22	9M FY 21	(%)	Q3 FY 22	Q2 FY 22	Q3 FY 21	QoQ(%)	YoY(%)
Total Income	12,905.6	9,773.8	32%	3,959.6	4,171.5	3,607.5	-5%	10%
Material cost	2,800.4	2,116.4		821.8	855.2	722.6		
Employee benefit expenses	1,970.6	1,638.1		610.4	635.0	619.3		
Other expenses	3,991.8	3,259.5		1,205.9	1,339.4	1,334.5		
Total operative expenses	8,762.8	7,014.0		2,638.1	2,829.6	2,676.4		
EBITDA	4,142.8	2,759.8	50%	1,321.5	1,341.9	931.2	-2%	42%
EBITDA (%)	32%	28%		33%	32%	26%		
Depreciation	540.4	529.0		188.1	181.4	195.5		
EBIT	3,602.5	2,230.8	61%	1,133.5	1,160.5	735.7	-2%	54%
EBIT (%)	28%	23%		29%	28%	20%		
Finance cost	121.7	250.9		29.7	28.9	90.5		
PBT	3,480.7	1,979.9	76%	1,103.8	1,131.6	645.2	-2%	71%
PBT (%)	27%	20%		28%	27%	18%		
Share of profit / (loss) of equity accounted investees	19.7			19.7				
Tax expenses	895.6	511.4		281.6	289.0	167.4		
PAT	2,604.7	1,468.6	77%	841.9	842.5	477.8	0%	76%
PAT (%)	20%	15%		21%	20%	13%		
Basic EPS(Rs.)	33.27	19.25		10.14	10.34	6.55		
Diluted EPS (Rs.)	33.27	18.95		10.14	10.34	6.45		

12-yr-old boy recovers after 65 days of ECMO support

Nirupa Vatyam & Vivek Chauhan | TNW

Hyderabad/Lucknow: A 12-year-old boy Shaurya Saran, suffering from multi-organ infection due to Covid-19 and on ECMO support for 65 days, has fully recovered.

The boy from Lucknow was airlifted to KIMS Hospitals for ECMO therapy for severe Covid-19 infection and was on life support utilizing the efficiencies of a veno-venous ECMO for over two months.

This is said to be the longest time any patient, who was put on ECMO support, has fully recovered in the country.

"When the patient came to us his lungs were fully affected and stiff and was unable to supply oxygen to



Shaurya Saran with medical team

dedicated doctors and support staff without which such a remarkable recovery would not have been possible.

The care given to the 12-year-old involved close monitoring of other organ functions, enhanced nutrition, physical rehabilitation, and advanced lung recovery manoeuvres while on the ECMO.

"Our continuous prayers were finally heard by God who returned our child from the clutches of death," said Shaurya's father Rajeveev Saran, an advocate in Lucknow high court.

"Despite giving all the best drugs available, when my son's condition didn't improve, doctor suggested to shift him to KIMS because it was the best option available in the country," he said.

He added that the hospital has one of the largest and most experienced ECMO teams in the country with de-

Unique case in Asia where a 12 year old boy hailing from Uttar Pradesh was treated by doctors by successfully treating him on ECMO for 65 days.

KIMS conducts breathing lung transplant surgery

CITY BUREAU
Hyderabad

Transplant surgeons at Krishna Institute of Medical Sciences (KIMS), Secunderabad, have conducted a 'breathing lung transplant' on a middle-aged patient, who was suffering from end-stage lung disease and was waiting for a donor lung since August.

According to a press release, breathing lung transplant involves preserving the functions of donor lungs

while they are being transported. Essentially it involves the donor lungs to be transported in a high-end container to keep them healthy by keeping them warm and nourished by blood and oxygen.

"Only a select few transplant institutions in the United States, Canada, and Austria take this approach to enhance the outcomes of lung transplants," Dr Sandeep Attawar said. The transplant teams utilised an organ conditioning system

manufactured by Swedish medical technology company XVIVO.

Dr Vijil Rahulan, chief, Transplant Pulmonology said, "Such state of the art systems improve organ function by perfusing donor organ with nutrient solutions and antibiotics to reduce injury to lung from cold ischemic transport in an icebox. It is also used to condition the lung with growth factors to enhance lung function and to reduce edema of the lung".

Conducted India's First Breathing Lung Transplant by using an organ condition system manufactured by Swedish medical technology.

Second smallest premature infant underwent closure of PDA using medical device without surgery

CITY BUREAU
Hyderabad, Dec 3: A couple from Hyderabad had premature twins after 3 years of marriage, that too in the IVF method. Both the babies were born at the gestational age of 26 weeks, and with a birth weight of 900 grams and 800 grams respectively. Both twins needed resuscitation measures at birth and were immediately admitted to the neonatal intensive care unit for breathing difficulty, particularly and extremely low birth weight.



One of the babies died after 12 hours of life. The surviving twin also developed multiple issues while undergoing treatment in NICU in the form of breathing difficulty with the need for ventilator support, feeding problems, infection and kidney issues. The baby also had a cardiac problem called PDA (patent ductus arteriosus) which is a persistent connection between the vessels supplying the body and the lung. Its persistence causes increased flow to the lungs and heart leading to heart failure and dependency on the ventilator. Also, it may cause kidney failure and bleed into the brain.

In this resolve, heart failure was present with poor kidney function and inability to come out of ventilator support due to the presence of PDA. Previously such cases needed surgical correction by incision from the chest. In some cases, kidney failure and internal bleeding in the brain also can happen. Doctors decided to solve the issue with the latest technology

without surgical intervention as the birth weight of the baby is just 600 grams. A medical device called Piccolo Occluder is the best option as per the pediatric cardiologists. It is a small self-expanding mesh device (smaller than a pea) that is inserted through one of the veins usually from groin without incision. It goes through one of the vein through minimally invasive catheter as small as 1.1 mm, enters the node

and released across it causing its closure.

The pediatric cardiology team of Dr Sudeep Verma, Consultant Pediatric Cardiologist and Dr Nagarajan, Consultant Paediatric Anaesthesiologist at KIMS Hospitals, Secunderabad went into the action. They closed the PDA using Piccolo Occluder, which is only 1/10 the size of a coin

on the 14th day of the life of the baby. Usually this is done by making incision through side of the chest by pediatric cardiac surgeon. But, the state-of-the-art technology available at KIMS hospitals made this possible without any surgery.

The procedure is very rare in this country as this is performed on a premature baby with very low weight, that too on the 14th day of life.

First PDA surgery was done on 800 grams newly born twins without open heart surgery.

KIMS sees 3 double-lung transplants in 24 hours

CITY BUREAU
Hyderabad

Doctors at the Krishna Institute of Medical Sciences (KIMS), Secunderabad, successfully performed three double-lung transplant surgeries on three recipients in a span of 24 hours, according to a press release.

The three double-lung transplants were performed by Chief Transplant Surgeon Dr Sandeep Attawar and his team. The three patients operated over the past 24 hours were at an advanced stage of lung failure and were waiting for donor lungs since many months.

While the first set of lungs were harvested from a brain

OO

A team of 12 specialist doctors ensured the harvested lungs were transported and transplanted within 6 to 8 hours

— DR SANDEEP ATTAWAR
CHIEF TRANSPLANT SURGEON, KIMS



dead person in Hyderabad, the second pair of donor lungs was harvested at a hospital in Ahmedabad, Gujarat, and were transported

to the city on a chartered aircraft. Both these were done in the second half on Wednesday (November 24), and the third pair of lungs was harvested in Visakhapatnam, Andhra Pradesh, on Thursday morning and transported to Hyderabad in a flight.

Dr Sandeep Attawar said, "A team of 12 specialist doctors ably supported by nursing staff made a highly coordinated effort and ensured the harvested lungs were transported and transplanted within 6 to 8 hours timeframe." Dr Vijil Rahulan, Dr Prabhat Dutta and Dr Srinivas were part of the team that conducted the transplants.

First ever in Asia, and possible an unprecedented instance in the world where doctors performed three double lung transplant surgeries on three recipients in a span of 24 hours.

కిమ్స్ వైద్యుల అరుదైనా చికిత్స

ఒక ప్రతిభాశీలకం: పద్మిని (7) చదువులో ముందంజలో ఉంది. ఆమె తండ్రి స్వల్ప దుకాణం నడుపుతారు. పద్మినికే మెదల వచ్చినట్లుగా నాన్నా రావడంతో పలు చోట్ల పరీక్షలు చేయించారు. చివరకు మెదలకు రక్తాన్ని సరఫరా చేసే ప్రధాన రక్తనాళానికి అత్యంత సమీపంలో కేన్సర్ కణితి ఏర్పడినట్లు గుర్తించారు. చికిత్స కోసం పలు ఆసుపత్రులకు వెళ్లారు. చివరకు కొంపూరిలో కిమ్స్ ఆసుపత్రిలో కన్సల్టెంట్ సైన్స్ సర్జన్ డాక్టర్ కృష్ణవైతన్యను కలిశారు. బాలికను పరీక్షించిన ఆయన కేన్సర్ కణితిని గుర్తించారు. ముందుగా కేన్సర్ కణితిని మెదలకు వెళ్ల రక్తనాళాల నుంచి వేరు చేశారు. తర్వాత ఒకసారి మళ్లీ సీడీ స్కాన్ చేసి ప్రమాదం ఏమీ లేదని నిర్ధారించుకుని కేన్సర్ కణితిని తొలగించారు. మెదల నిర్ధారించినందుకు ఏమీ తర్వాత కొన్ని ప్రయోగం ఏగించాల్సి వచ్చిందని. ఈ సందర్భంగా డాక్టర్



చిన్నారిని పరీక్షిస్తున్న డాక్టర్

కృష్ణవైతన్య మాట్లాడుతూ... మెదల రక్తనాళాలకు దగ్గరగా ఉండే సెల్ల్యులర్ ఆస్ట్రోమాస్ ఆస్ట్రోమాస్ కణితులకు శస్త్ర చికిత్స చేయడం చాలా సంక్లిష్టమైన ప్రక్రియ అన్నారు. కేన్సర్ కణితిని తొలగించడానికి శస్త్రచికిత్సకు ముందు ప్రధాన రక్తనాళాలను తొలగించామని, బాలికకు మరోసారి కేన్సర్ రాకుండా ఉండి, జీవనశాలం కూడా పెరుగుతుందన్నారు.

Doctors save a 7 year old girl child suffering from a rare Cervical Tumor.

కిమ్స్ లో విజయవంతంగా కిడ్నీ ఆపరేషన్

అశ్వినిపాపం (గాజువాక): అల్పవయస్కులకు కిడ్నీ ఆపరేషన్లు ఏలానగర్లోని కిమ్స్ వాక్ ఆసుపత్రిలో వైద్యులు విజయవంతంగా పూర్తి చేశారు. ఆసుపత్రి బిస్కెల్లోని అత్యున్నత స్థాయిలో ముఖ్యమంత్రి వారం తెలిపిన వివరాలకు ఉన్నాయి.

విశాఖ నగరానికి చెందిన వసంతి శివప్రసాద్ (48) వ్యక్తిత్వంగా బ్యాంక్ ఉద్యోగి. ఈయనకు 1989లో కిడ్నీ ఫిష్ట్యూలో రాళ్లు ఏర్పడ్డాయి. అప్పుడు ఓపిసే సర్జరీ చేసి రాళ్లు తొలగించారు. తిరిగి అదే సమస్య 2001లో రావడంతో డి.వి. వెల్లి చికిత్స చేయించుకున్నాడు. అయితే అక్కడ వైద్యులు మొదటిసారి ఆపరేషన్ చేసి సమయంలో చేసిన రంధ్రం పక్కనే రంధ్రం చేసి కిడ్నీలో రాళ్లు తొలగించారు. కొంత కాలానికే ఆ రంధ్రం సహాయంతో ఆపరేషన్ విజయవంతం చేశాడు.



బాలకుడు వసంతి శివప్రసాద్

నుంచి ఏముకారం మొదలైంది. ఈ ప్రయత్నంలో కిమ్స్ ఆసుపత్రికి వచ్చిన బాలికను పరీక్షించిన వైద్యులు... ఏముకారం వల్ల ఈ ప్రాంతంలో ఉన్న ప్రేగులు అతుక్కుపోయాయని, మరీ వైపు కిడ్నీ పని చేయకపోవడం గుర్తించారు. లోగి ప్రాణాలు కాపాడడం కోసం తప్పవని పరిస్థితిలో పాల్గొన్న డాక్టర్ పాపం అతుక్కుపోయిన ప్రేగులను తొలగించాల్సి వచ్చిందని డాక్టర్ ముఖ్యమంత్రి తెలిపారు. ఈ ఆపరేషన్ చేయడానికి సుమారు 12 గంటల సమయం వట్టిందన్నారు. పాపం తొలగించామని, సీడీ స్కాన్ సహాయంతో ఆపరేషన్ విజయవంతం చేశామన్నారు.

A complex kidney surgery (known as right nephrectomy with inferior vena cava) repair was performed by doctors on a 46 years patient suffering from kidney stones.

Update on Sunshine Hospital

SUNSHINE HOSPITAL - BRIEF PROFILE



SUNSHINE
HOSPITALS



Dr. A.V. Gurava Reddy
Managing Director



Dr. A. Bhavani
Director



SECUNDERABAD



GACHIBOWLI



KARIMNAGAR

- Started in 2009
- Founders: Dr. A.V. Gurava Reddy & Dr. A. Bhavani
- Second largest Orthopedic practice in South East Asia

- Locations: Secunderabad, Gachibowli & Karimnagar
- Beds Capacity: 600+
- Key Specialities: Ortho Sciences, Cardiac Sciences & Gastro Sciences

SUNSHINE
ORTHROBOTICS

A Designated Global Centre of
Excellence for Robot-assisted Joint Replacements

Mako
Smartrobotics

Know More Cut Less



- 1st Hospital in INDIA with ISOC Membership (Only 2 from India have this membership)
- 4000 Total joint replacements performed on average, every year
- More than 10,000 surgeries annually, across all the orthopaedic sub-specialities
- More than 700 Robotic Knee replacements done in less than 18 months - Fastest in the World!

Brand Integration:

- Post renovation work which is expected to finish in next 2 quarters, Sunshine Gachibowli Unit will be renamed as KIMS-Sunshine Hospital.
- The existing Sunshine Secunderabad Unit has severe space constraints and the building is also on lease. We would be moving to a newer space (around 1.5 KMs away) by Dec 2022 and this unit will be renamed as KIMS-Sunshine Hospital.

Operational Integration:

- IT Infrastructure updation is complete and the both the units are now in sync with KIMS IT Infra.
- Assessment and Realignment of manpower along with implementation of KIMS HR policy is in progress. This will be completed by the end of Q4 FY22.
- Other key integration of Centralised Procurement for all medical and non-medical purchase work is fast nearing completion.

Clinical Integration:

- We have identified and started work on strengthening key clinical departments which have the potential to be the growth engines for Gachibowli unit. The on boarding of doctors in these departments will be complete in the next two quarters.
- On boarding of clinical talent for Secunderabad unit will happen closer to second quarter of next financial year. Our expected date to close all key clinical hiring is by 2nd quarter of next financial year.

SUNSHINE HOSPITALS -CONSOLIDATED FINANCIAL SNAPSHOT (P&L)

Ind AS

P&L Summary (In INR Mn)	Nov-Dec '21 (2 Months)
Revenue (Inc. Other Income)	745.26
EBITDA	179.19
EBITDA %	24.04%
Finance Cost	23.80
Depreciation	49.47
PBT	105.92
PAT	71.92
EBITDA	179.19
IND AS Adjustment	34.10
EBITDA - Pre Ind AS Adjustment (Rental)	145.09

Source: Audited Financial Statement

Update on Expansion Plans

EXPANSION PLANS

Units	Current Beds	Incremental Beds	New Departments	Approx. Capex	Approx. Timeline (Starting April 2021)
Kondapur	200	500	All Specialities	300 Cr	36-42 months
Vizag	434	50	Cancer Centre	15-20 Cr	24 months
Anantapur	250	150	Cancer Centre / Mother & Child	50-60 Cr	36-48 months
Ongole	350	-	Cancer Centre	15-20 Cr	36-42 months
Bangalore	-	350-400	All Specialities	300-330 Cr	36 months
Chennai	-	350-400	All Specialities	400 Cr	36 months
Western / Central India	-	250-300	All Specialities	300 Cr	24-36 months

Thank You